Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Adulsa Therapeutics Corp. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, which indicates a singular focus for the current legal proceedings. The prosecution is limited to 1 distinct art unit, pointing to a specific technical classification for the pending invention. This concentration of resources suggests a highly targeted approach to securing intellectual property rights for this biotechnology innovation.
BARSKY, JARED is the busiest examiner for the company, overseeing 1 pending office action. Since the busiest examiner pending count of 1 represents the total volume of pending work, this individual is the sole decision-maker for the active applications at this time. The strategy must be tailored to the specific expectations of this 1 examiner to move the 1 pending action toward allowance within the identified art unit. Monitoring the examiner's specific rejection patterns will be crucial for a successful outcome.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.3% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026229 | METHODS OF INHIBITING DISEASES CAUSED BY RESPIRATORY VIRUSES | BARSKY, JARED | 83d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18026229 | METHODS OF INHIBITING DISEASES CAUSED BY RESPIRATORY VIRUSES | BARSKY, JARED | 1628 | §103 | Non-Final OA | 83d | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdulsa Therapeutics Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jared Barsky has the most, with 1 of Adulsa Therapeutics Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
